X4 Pharmaceuticals, Inc. Common Stock (XFOR) Stock
Key stats
- Market cap
- $272.65M
- Price / Earnings ratio
- -2.8x
- EPS (TTM)
- -$139.00
- Volume
- Loading
- 52-week high
- $4.83
- 52-week low
- $2.43
Source: third-party data provider, as of October 21, 2026
Compare with XFOR
Recent news

Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
XFOR

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
XFOR

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
XFOR

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
XFOR
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 50.12
- MACD 12/26/9
- -0.21
- EMA 9 of MACD
- -0.25
- MACD histogram
- 0.04
- SMA 50
- $3.48
- Price below SMA 50
- EMA 50
- $3.29
- Price below EMA 50
- SMA 200
- $3.83
- Price below SMA 200
- EMA 200
- $3.70
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 20, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.24 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
XFOR

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
XFOR

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
XFOR

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
XFOR

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
XFOR

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know
XFOR

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
XFOR

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
XFOR

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
XFOR

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy
XFOR
News tone: automated (AI) classification of the article's content, not a price prediction.
About X4 Pharmaceuticals, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Adam R. Craig M.B.A., M.D., Ph.D. | Executive Chair | 1966 |
| Mr. John P. Volpone M.B.A. | President & COO | 1975 |
| Mr. David H. Kirske | CFO, Treasurer & Corporate Secretary | 1954 |
| Dr. Richard Peters M.D., Ph.D. | Founder | 1962 |
| Dr. Renato T. Skerlj Ph.D. | Founder | — |
| Dr. Keith T. Flaherty M.D. | Founder & Member of Corporate Advisory Board | 1971 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 21, 2026
Technical indicators
- RSI 14
- 50.12
- MACD 12/26/9
- -0.21
- EMA 9 of MACD
- -0.25
- MACD histogram
- 0.04
- SMA 50
- $3.48
- Price below SMA 50
- EMA 50
- $3.29
- Price below EMA 50
- SMA 200
- $3.83
- Price below SMA 200
- EMA 200
- $3.70
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 20, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +7.3 | -14.8 | -45.0 | |||||||||
| 2022 | -20.2 | -26.8 | -2.8 | -31.7 | -2.4 | -22.2 | +23.1 | -23.8 | +64.4 | +25.8 | -20.6 | -31.0 |
| 2023 | +7.7 | -9.8 | -8.4 | +62.4 | +29.3 | -12.6 | -4.8 | -26.4 | -16.2 | -19.1 | +3.8 | +13.3 |
| 2024 | -11.4 | +15.6 | +37.6 | -20.6 | -8.6 | -42.0 | +35.7 | -9.8 | +1.5 | -21.2 | -24.3 | +97.8 |
| 2025 | -6.9 | -34.2 | -34.4 | -35.2 | -9.3 | -50.1 | -9.7 | +135.0 | -1.4 | +11.6 | -11.0 | +27.0 |
| 2026 | -4.9 | -13.6 | +21.5 | -6.4 | +2.9 | +13.6 | -2.7 | -1.2 | -28.7 | +6.7 |



